Table 1.
Inhaled formulations available for treating pulmonary infections.
| Formulation | Drug | Pharmaceutical Dosage Form | Indication |
|---|---|---|---|
| Tobi® * | Tobramycin | Solution for inhalation | Cystic fibrosis patients infected with Pseudomonas aeruginosa |
| Betkis® * | Tobramycin | Solution for inhalation | Cystic fibrosis patients infected with P. aeruginosa |
| Cayston® * | Aztreonam | Solution for inhalation | Cystic fibrosis patients infected with P. aeruginosa |
| Tobi® Podhaler * | Tobramycin | Dry powder inhaler | Cystic fibrosis patients infected with P. aeruginosa |
| Kitabis® Pak * | Tobramycin | Solution for inhalation | Cystic fibrosis patients infected with P. aeruginosa |
| Arikayce® * | Amikacin | Liposomal inhalation suspension | Nontuberculous mycobacterial lung disease |
| Opelconazole | Opelconazole | Dry powder inhaler | Aspergillosis |
| PUR1900 | Itraconazole | Dry powder inhaler | Fungal pulmonary infections |
| Voriconazole | Voriconazole | Dry powder inhaler | Fungal pulmonary infections |
| Apulmiq | Ciprofloxacin | Liposomal inhalation suspension | Chronic lung infections with P. aeruginosa |
| MRT5005 | Ciprofloxacin | Lipid nanoparticles | Cystic fibrosis |
* Approved formulations.